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Abstract 
Background: A gas chromatography mass spectrometry (GCMS) method for the determination of diclofenac in 
human plasma has been developed and validated.
Results: This method utilizes hexane which is a relatively less toxic extraction solvent compared to heptane and ben-
zene. In addition, phosphoric acid and acetone were added to the samples as deproteination agents, which increased 
the recovery of diclofenac. These revised processes allow clean extraction and near-quantitative recovery of analyte 
(approx. 89–95 %). Separation was achieved on a BP-1 column with helium as carrier gas. The molecular ion peaks of 
the indolinone derivatives of diclofenac ion (m/z 277) and the internal standard, 4-hydroxydiclofenac ion (m/z 439) 
were monitored by a mass-selective detector using selected ion monitoring (SIM) mode. The linear range for the 
newly developed and highly sensitive assay was between 0.25–50 ng/mL. The detection and lower quantifiable limits 
were 0.125 and 0.25 ng/mL, respectively. The inter-day and intra-day coefficients of variation for high, medium and 
low quality control concentrations were less than 9 %. The robustness and efficacy of this sensitive GCMS method 
was further demonstrated by using it for a pharmacokinetic study of an oral dosage form of diclofenac, 100 mg of 
modified-release capsules (Rhumalgan XL), in human plasma.
Conclusions: This method is rapid, sensitive, specific, reproducible and robust, and offers improved sensitivity over 
previous methods. This method has considerable potential to be used for detailed pharmacokinetics, pharmacody-
namics and bioequivalence studies of diclofenac in humans.
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Background
Sodium 2-(2,6-dichlorophenyl-aminophenyl acetate 
(diclofenac) salt is a nonsteroidal anti-inflammatory drug. 
Clinically, it is mostly used for the treatment of pain 
caused by inflammation [1–6]. In humans, “the absorp-
tion, distribution, metabolism, and excretion” (ADME) 
studies of diclofenac show that it has high inter- and intra-
subject variability [7–17] that may arise from pharmacog-
enomics differences amongst individuals and/or precision 
in measurement procedures. Furthermore, due to wide 
availability of diclofenac formulations, there is an inter-
est in having robust and sensitive assays for diclofenac 
quantitation for pharmacokinetics studies. This could be 
especially important in developing countries with nascent 
pharmaceutical industries, who may synthesize and sell 
their own diclofenac formulations. To start this inquest, 
we have developed a gas chromatographic mass spectro-
metric (GCMS) method for the detection and quantifica-
tion of diclofenac concentrations in human plasma. Many 
methods have been developed for the determination of 
diclofenac in biological specimens e.g. high pressure liquid 
chromatography with ultra violet detection (HPLC–UV) 
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[18–21], HPLC with electrochemical detection [22, 23] 
and online micro-dialysis with liquid chromatography 
[24], electro-membrane extraction (EME) and pulsed- 
electro-membrane extraction (PEME) coupled with HPLC 
[25], liquid chromatography mass spectrometry (LCMS) 
[26, 27] and GCMS methods [28–31].
While GCMS methods have been the favorite choice 
in the past, many derivatisation reagents have been tried 
and tested. Borenstein et  al. used pentafluoropropionic 
anhydride (PFPA) as a derivatising agent with lower limit 
of quantification (LOQ) of 1 ng/mL with a 95 % recovery 
[30]. Choi et  al. used a mixture of PFPA and a mixture 
(1000:2:3,v/w/w) of N-methyl-N-trimethylsilyltrifluoro-
acetamide (MSTFA), ammonium iodide (NH4I), and 
dithioerythritol (DTE) as derivatisation reagent. With 
this method the LOQ was 0.5  ng/mL and the recovery 
approximately 97 % [32]. Yilmaz et al. described a method 
where MSTFA was used as the derivatising agent (silylat-
ing reagent), and the hydroxyl group of diclofenac was 
O-silylated. Here the LOQ was 5 ng/mL with a recovery 
of about 96 % [31]. In our work PFPA was chosen as the 
best derivatising agent due to it giving a better sensitivity 
and maximum recovery.
HPLC-UV methods have been reported to measure 
plasma diclofenac in the range ca. 10–100 ng/mL [18–20]. 
Plasma matrix and other diclofenac metabolites are also 
known to cause interferences in accurate diclofenac esti-
mation in human matrices [29]. To ensure good specific-
ity and reproducibility, lengthy and comprehensive sample 
preparation procedures are often required [16–18]. On the 
other hand, mass spectrometric methods offer potentially 
better precision, accuracy, sensitivity and recovery, with a 
detection limit of between 0.2–2  ng/mL [26, 27, 30, 33]. 
The reported mass spectrometric methods used benzene 
and heptane as extraction solvents. However, the sensitiv-
ity of these methods was not good enough to carry out a 
thorough and accurate lower dose pharmacokinetic analy-
sis of diclofenac in human plasma. In the present study, we 
have modified existing methods [29–31] introducing hex-
ane, acetone and sodium bicarbonate to develop a more 
sensitive, specific and reproducible method for the deter-
mination of diclofenac in human plasma.
Having developed and validated a method for the quan-
tification of diclofenac in plasma we sought to demonstrate 
a proof-of-concept application. For this purpose, plasma 
samples were obtained from 30 volunteers who had been 
given an oral dosage of 100 mg of diclofenac sodium (Rhu-
malgan XL 100  mg modified-release capsules). Human 
plasma samples were analysed between 0 and 12 h to eval-
uate the pharmacokinetic parameters of diclofenac.
Methods
Chemicals and reagents
Diclofenac sodium salt (analytical standard), 4-hydroxy-
dichlofenac (>98 % pure), concentrated phosphoric acid 
solution of 85  % (w/v), derivatising agent PFPA (99  % 
pure) and sodium hydrogen carbonate (>99.7  % pure) 
were purchased from Sigma-Aldrich Ltd Dorset, UK. 
Methanol (MeOH), acetone, chloroform, water and 
hexane of HPLC grade were purchased from Hichrom 
Ltd, Reading, Berks, UK. Drug free human plasma was 
obtained from TCS Biosciences Ltd, Buckingham, UK.
Apparatus and assay conditions
GCMS was performed with a Hewlett Packard model 
6890 Gas Chromatograph (GC) fitted with a 6890 auto-
injector for a pulsed splitless injection coupled to a model 
5973 Mass Selective Detector (MSD) (Agilent Technolo-
gies, USA). Separation was achieved using a BP-1 fused 
silica capillary column (15  m  ×  250  µm  ×  0.25  µm). 
Helium (99.95 %, BOC Gases, Surrey, UK) was used as a 
carrier gas at a flow-rate of 1.2 mL/min. The injection vol-
ume was 2 µL. The syringe size was 10 µL. Pulse pressure 
and pulse time were 20 psi and 0.5 min respectively. Total 
run time was 14.5 min. Injector temperature was 280 °C. 
The initial oven temperature was 150 °C, whilst the final 
oven temperature was 300  °C. The final high tempera-
ture purged residual materials from the column. The col-
umn temperature was initially held at 150  °C for 4  min 
(total run time 4  min), increased at 4  °C/min to 180  °C 
in 7.5 min and held there for 0.5 min (run time 12 min), 
then increased at 60 °C/min to 300 °C in 2 min and held 
there for 0.5 min (run time 14.5 min). Carrier gas flow-
rate at the split vent was 54.3 mL/min. The injector was 
set to auto clean itself by pre-injecting hexane.
The mass selective detector was operated in the 
selected ion monitoring mode (with electron impact) and 
set at m/z [M+] 214, 242 and 277 and m/z 376 and 439 
for the detection of diclofenac and 4-hydroxydiclofenac, 
respectively. The corresponding retention times of 
diclofenac and 4-hydroxydiclofenac were 7.5  min and 
8.5  min respectively (for a 100  ms dwell). The relative 
retention times of diclofenac to 4-hydroxydiclofenac was 
1.13 with a standard deviation of 0.01. Solvent delay was 
3  min, electron multiplier accelerating voltage 2494  V 
and electron ionisation energy 70  eV. Mass spectrom-
eter source, quadrupole and transfer line temperatures 
were 230, 150 and 280  °C, respectively. The accelerating 
voltage was set at 3.5 kV. The system was controlled and 
detector output data was processed using a Chemstation 
version B.00.02 software.
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Preparation of standards
A stock solution of 1  mg/mL was prepared by adding 
10.78  mg of Diclofenac in 10  mL (MeOH) (Final conc. 
1.078 mg/mL). Working solutions were prepared by serial 
dilutions of the stock solution. A 0.45 mg/mL stock solu-
tion of 4-hydroxydiclofenac was prepared by dissolv-
ing 4.5 mg of 4-hydroxydiclofenac in 10 mL MeOH. The 
concentration of the working internal standard solution 
of 4-hydroxydiclofenac was 0.0045 mg/mL. All solutions 
were stored at −20 °C.
Preparation of 1M phosphoric acid
33.3 mL of concentrated phosphoric acid solution of 85 % 
(w/v) strength was diluted with 500 mL deionised water 
to give a solution of 1  M concentration. The bottle was 
labelled and an expiry date of 2 months from the date of 
preparation was applied. The solutions were found to be 
stable for this duration. The solution was stored at room 
temperature.
Preparation of 0.08 M sodium hydrogen‑carbonate solution
Approximately 0.672  g of sodium hydrogen carbonate 
was weighed and diluted with 100  mL of HPLC grade 
water, stored at room temperature with an expiry date of 
2 months.
Sample preparation
Appropriately labelled Pyrex glass tubes (100 × 13 mm) 
with screw caps were used. Plasma samples (1  mL) 
were added to the sample tubes. An internal stand-
ard of 4-hydroxydiclofenac (25  μL) of concentration 
0.0045 mg/mL was added and the mixtures acidified and 
vortex mixed with1 M phosphoric acid (1 mL). Then, to 
all tubes, 1 mL of acetone was added for deproteination 
followed by vortex mixing. Next, 5 mL of n-hexane was 
added, the tubes capped and the samples placed on a 
roller mixer for 15 min. All the tubes were centrifuged 
at 1400×g for 5 min at room temperature. The top hex-
ane layer was transferred to glass screw-capped tubes 
to which 1  mL of 0.08  M sodium hydrogen carbonate 
solution was added for basification and to increase par-
tition of the drug into the aqueous layer. The tubes were 
capped and again placed on a roller mixer for 15  min 
and centrifuged at 3000×g for 5  min. The upper hex-
ane layer was aspirated and discarded. Phosphoric acid 
(1 mL) was then added, followed by 5 mL of n-hexane. 
The tubes were then placed on a roller mixture for a 
further 15  min and centrifuged for 5  min at 3000×g 
and the top hexane layer was transferred to glass tubes 
(100  ×  13  mm, without screw cap). Hexane was then 
evaporated off under a stream of nitrogen with the 
heater block set at 35 °C.
Derivitisation of the samples
n-Hexane (975 μL) and 25 μL (v/v) of PFPA were added 
to the dried residue and the tubes vortex mixed for 
30  s. The samples were allowed to react for 30  min on 
a heater block at 35  °C and gently evaporated under a 
stream of nitrogen. The tubes were allowed to cool to 
room temperature and the derivatised compound was 
reconstituted into 80 μL of chloroform. The sample was 
transferred to autosampler vials and the GCMS autosa-
mpler programmed to inject 2 μL of the sample. Figure 1 
shows the indolinone derivatives formed from derivatisa-
tion of diclofenac sodium and 4-hydroxydiclofenac using 
the derivatising agent PFPA.
This newly developed analytical method was tested in a 
human pharmacokinetic study. Plasma samples obtained 
after administration of 100 mg of oral diclofenac sodium 
in participating volunteers were analysed to quantitate 
the plasma concentrations of the drug over a 12 h period. 
Kingston University research ethics committee approved 
the protocol and the volunteers provided informed writ-
ten consent to participate.
Validation
Calibration curve and analysis
The working standard solutions for plasma analysis were 
made by serial dilution of the stock solutions to final con-
centrations of 10, 20, 40, 200, 400, 1000 and 2000 ng/mL 
in methanol. Calibration standards were obtained by spik-
ing 25 µL of each of these standards into 975 µL of human 
plasma to produce concentrations of 0.25, 0.5, 1, 5, 10, 25 
and 50 ng/mL. The samples for the standard curve were 
processed as described in the materials and method sec-
tion. The ratio of peak area of diclofenac to that of the 
internal standard was plotted versus the concentration 
of the diclofenac in the calibration standard and a least-
squares linear regression analysis was performed. Values 
of unknown plasma concentrations were determined from 
the regression line of this calibration curve. The working 
quality control solutions in methanol for plasma analy-
sis were made by serial dilution of the stock solutions to 
obtain final concentrations of 10, 20, 44, 600 and 1600 ng/
mL. Quality controls were obtained by spiking 25  µL of 
each of these standards into 975 µL of human plasma to 
produce concentrations of 0.25, 0.5, 1.1, 15 and 40 ng/mL. 
All methanolic solutions were stored at 2–8  °C with an 
expiry of 7 days, due to their short stability in methanol, 
while plasma samples were stored at −20 °C.
Intra–inter day precision and accuracy
The accuracy and precision of the method was deter-
mined by assaying 0.5 mL aliquots of ethylene-diamine-
tetra-acetic acid (EDTA) human plasma fortified with 
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four quality control (QC) samples of 0.5, 1.1, 15.0 and 
40.0  ng/mL of diclofenac. These fortified samples were 
later assayed by GCMS. To assess the inter-assay preci-
sion and accuracy, samples were analysed on five sepa-
rate days. To assess the intra-assay precision, these same 
QC concentrations were analysed and compared during 
1 day.
Linearity, sensitivity and specificity
The ratio of diclofenac and 4-hydroxydiclofenac 
responses were plotted by GCMS ChemStation Version 
3.1 software to determine the linearity. A calibration 
point was rejected as an outlier if the back-calculated 
concentration for a calibrator (on the basis of the cor-
responding calibration curve) deviated by more than 
15  % at all concentrations covered by the calibration 
range, except at the lower limit of quantitation (LLOQ), 
where a deviation of 20 % was acceptable. A calibration 
curve was allowed with a minimum of four acceptable 
calibration levels. These criteria were based on the US 
Food and Drug Administration (FDA) “Bioanalytical 
Method Validation: Guidance for Industry” protocol 
[34].
The analytical method was able to determine diclofenac 
and 4-hydroxydiclofenac (internal standard) in plasma 
without significant interference from other endogenous 
compounds. The specificity of the validated assay pro-
cedure was shown by analysing 6 blank plasma samples 
from subjects not exposed to diclofenac, it was then 
spiked and recoveries calculated.
Extraction recovery
Absolute extraction recovery of diclofenac from human 
EDTA plasma was determined at three concentration 
levels: 1.1, 15 and 40 ng/mL. The area ratio response of 
diclofenac to internal standard in the extracted sample 
divided by the area ratio response determined in an un-
extracted sample and multiplied by 100 gave the percent 
recovery. These samples were extracted, as described 
earlier, except that the internal standard was added to 
the collected extract. The concentrations of the spiked 
plasma samples were calculated from the curve and com-
pared to the theoretical values in order to calculate the 
extraction recovery.
Stability
The stability of diclofenac in human EDTA plasma was 
determined in processed sample extracts over at least 
24 h period and also by three repeated freezing and thaw-
ing cycles.
Fig. 1 Formation of indolinone derivatives for both diclofenac-Na and 4-hydroxydiclofenac in the presence of derivatising agent PFPA
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Stability of diclofenac in EDTA plasma to repeated freezing 
and thawing cycles
Human EDTA plasma samples at concentration of 
QCL = 1.1 ng/mL, QCM = 15 ng/mL and QCH = 40 ng/
mL were subjected to three freezing and thawing cycles. 
The time span for freeze/thaw cycles was 72 h with each 
freeze/thaw cycle lasting for 24 h with time points 24, 48 
and 72  h. The results obtained after each freezing and 
thawing cycle were expressed as a percentage change 
from the results for QCL = 1.1 ng/mL, QCM = 15 ng/
mL and QCH =  40  ng/mL in the intra-assay run (vali-
dation run-1, these samples were prepared fresh and 
had not experienced any freezing conditions). The test 
compound was considered to be stable if the percentage 
change from freshly prepared samples was within ±15 % 
of the nominally spiked level.
Pharmacokinetics study
The pharmacokinetic study chosen, set out to analyze 
diclofenac sodium in human plasma. For this study, 
plasma samples were obtained from 30 volunteers who 
had been given an oral dosage of 100  mg of diclofenac 
sodium (Rhumalgan XL™ 100  mg modified-release cap-
sules). Diclofenac concentrations in plasma were meas-
ured between 0 and 12  h, (blood being collected every 
hour) in order to evaluate the pharmacokinetic param-
eters of diclofenac. Kingston University Faculty of Science 
Research Ethics Committee approved the protocol and the 
volunteers provided informed written consent to partici-
pate. The pharmacokinetic study was conducted accord-
ing to the principles of the Declaration of Helsinki [35]. 
According to FDA guidelines for generic drugs studies, the 
area under the curve (AUC) was calculated using a linear 
trapezoidal method, by applying non-compartmental data 
analysis. The method developed was used to investigate 
the plasma profile after oral dosing of diclofenac sodium 
100 mg capsules in 30 healthy young male volunteers.
Results and discussion
Diclofenac sodium and 4-hydroxydiclofenac react 
with the derivatising agent PFPA to form indolinone 
derivatives, which upon electron ionisation gave rise 
to diclofenac ions at m/z 277, 242 and 214, whilst 
4-hydroxydiclofenac gave ions at m/z 439 and 376.
Calibration curve and analysis
Figure  2 displays a representative chromatogram of 
blank plasma spiked with 0.25  ng/mL of diclofenac and 
0.0045  ng/mL of the internal standard. Pooled normal 
human plasma yielded relatively clean chromatograms 
with no significant interfering peaks. Both diclofenac and 
the internal standard showed sharp, well-defined peaks at 
retention times of 7.5 and 8.5 min, respectively.
The mass spectra of diclofenac and the internal stand-
ard are shown in Fig.  3a, b. The derivatised indolinone 
ions for diclofenac and its internal standard fragment dif-
ferently in the mass spectrometer giving rise to two dis-
tinctly different indolinone ions as shown in Fig. 3a, b.
Linearity, sensitivity and specificity
During the validation study, calibration curves were 
generated over a diclofenac concentration range of 
0.25–50  ng/mL. The method showed good sensitivity, 
specificity and linearity in the concentration range 0.25–
50 ng/mL. The plots were linear over the concentration 
range 0.25–50 ng/mL.
The curves were all linear with a mean coefficient of 
determination of 0.9996, see Table  2. To evaluate the 
curve, the observed responses for the individual stand-
ards were substituted back into the equation in order to 
calculate the predicted concentrations based on the cali-
bration curve. The limit of quantitation was 0.25 ng/mL. 
Using a signal-to noise ratio measure, the estimated limit 
of detection was 0.125 ng/mL.
Furthermore, as can be seen from the Table 1, the per-
centage recovery of diclofenac in spiked plasma samples, 
was well within the accepted limit of 85–115 %, thereby 
showing no matrix effects. No notable peaks were seen 
in the region of interest when six blank plasma samples 
were analyzed, see Table  1. The retention time region 
of the chromatograph where diclofenac and 4-hydroxy-
diclofenac eluted was clear in these samples and dem-
onstrated the specificity of the validated analytical 
procedure. No interference from endogenous com-
pounds or metabolites of diclofenac was found around 
the elution times, however a matrix peak was observed at 
a different retention time see Fig. 4.
Intra and Inter assay accuracy and precision
The inter-assay accuracy and precision were calculated 
from results obtained from quality control samples 
(N = 6) analysed at four concentrations (0.5, 1.1, 15 and 
40  ng/mL of diclofenac in EDTA plasma representing 
LLOQ, QCL, QCM and QCH respectively) on three sep-
arate occasions, see Table 2.
Recovery
Our initial attempts gave a respectable recovery of the 
spiked drug at ca. 60  %. However, further experiments 
using acetone and sodium bicarbonate showed that the 
simple addition of these two reagents resulted in a dra-
matic increase in recovery by 50 %. Final recoveries were 
calculated during validation runs as shown in Table 2.
Intra and inter day precision (coefficient of variation) 
ranged between 2.41–6.33 and 7.51–8.87  % respec-
tively, while intra and inter day accuracy ranged between 
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88.98–95.82 and 95.73–102.01  % respectively. The per-
cent recovery of the three QC’s ranged between 89.86–
94.76 %, see Table 2.
Freezing and thawing cycles
The QCL  =  1.1  ng/mL samples gave a mean result 
of 1.96, 2.02 and 1.88  ng/mL (n  =  6) with the cor-
responding percentage change from freshly pre-
pared samples of  +9.49,  +12.93 and  +4.83  % for 
Fig. 2 Chromatographs of diclofenac (0.25 ng/mL) and 4-hydroxydiclofenac (0.0045 ng/mL) derivatives in plasma
Fig. 3 a Mass spectrum showing abundant ions for diclofenac derivative. b Mass spectrum showing abundant ions of 4-hydroxydiclofenac deriva-
tive
Table 1 Recovery of  diclofenac standards when  added 
to blank plasma showing no notable matrix effect (n = 6)
Nominal concentration  
(ng/mL)
Recovery
Mean ± SD (%)
0.5 97.45 ± 6.21
1.1 98.63 ± 5.22
15 100.52 ± 4.73
40 97.59 ± 7.21
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freezing and thawing cycles 1, 2 and 3 respectively. 
The QCM = 15 ng/mL samples gave a mean result of 
18.85, 18.97   and 19.19  ng/mL (n  =  6) with the cor-
responding percentage change from freshly prepared 
samples of  +3.42,  +4.11 and  +5.29  % for freez-
ing and thawing cycles 1, 2 and 3 respectively. The 
QCH = 40 ng/mL samples gave a mean result of 51.05, 
51.23 and 50.85  ng/mL (n =  6) with the correspond-
ing percentage change from freshly prepared samples 
of +4.32, +4.69 and +3.91 % for freezing and thawing 
cycles 1, 2 and 3 respectively. The data indicated that 
diclofenac was stable in EDTA plasma to at least three 
freezing and thawing cycles.
The validation results indicated that the proposed 
method is more efficient in detecting the non-steroidal 
anti-inflammatory drug diclofenac, in human plasma 
even at very low levels when only ca. 1000 µL of human 
plasma was processed. Under the extraction and chroma-
tographic conditions employed, there were no detectable 
interferences by endogenous materials present in human 
plasma.
Three freezing and thawing cycles showed that 
diclofenac was stable in EDTA plasma. The average per-
cent variation from freshly prepared EDTA samples, 
at three concentration levels, were 9.1, 4.27 and 4.3  % 
respectively.
Many GCMS derivatization reagents has been tried 
and tested in the past to get maximum sensitivity and 
ultimate recovery of diclofenac from human plasma. 
Choi et  al. showed that when a mixture of PFPA and a 
mixture (1000:2:3, v/w/w) of N-methyl-N-trimethyl-
silyltrifluoroacetamide (MSTFA), ammonium iodide 
(NH4I), and dithioerythritol (DTE) were used as deriva-
tisation reagents, the lower limit of quantification (LOQ) 
was 0.5  ng/mL. While we have used PFPA as a deriva-
tisation reagent, with an improved LOQ of 0.25  ng/mL 
and a similar recovery to Choi’s work [32]. Yilmaz et al. 
described a method where MSTFA was used as deriva-
tising agent (silylating reagent). Here, the LOQ was a 
factor of ten higher at 5 ng/mL with a recovery of about 
96 % [31]. Others who have used PFPA as a derivatising 
agent include Borenstein et al. who achieved a lower limit 
of quantification (LOQ) of 1  ng/mL with a 95  % recov-
ery and Kadowaki et al. who reported a LOD (LOQ not 
reported) of 0.2 ng/mL and recoveries of ca. 83 %. How-
ever, they used benzene as an extraction solvent which is 
more toxic [29]. Electro-membrane extraction (EME) and 
pulsed electro-membrane extraction (PEME) coupled 
with HPLC gave an LOD of 10 ng/mL an LOQ was not 
reported [25].
Our method has given a considerable improvement 
over the above methods with increased sensitivity LOQ 
Fig. 4 Overlay chromatograms of six blank plasma samples showing specificity
Table 2 Summary of assay validation results including precision and accuracy data
LOD limit of detection, % CV coefficient of variation
Analyte  
(ng/mL)
QC 
(ng/
mL)
Linear range 
(ng/mL)
LOD 
(ng/
mL)
r2 Intra-day (N = 6) Inter-day (N = 6) Recovery %
Precision % CV Accuracy % Precision, % CV Accuracy %
Diclofenac Na 0.5 0.25–50 0.125 0.9996 6.33 95.82 8.64 102.01
1.1 2.41 89.45 8.87 99.54 94.76
15 5.39 91.12 7.70 99.47 91.77
40 3.41 88.98 7.51 95.73 89.86
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0.25 ng/mL and greater than 90 % recovery. Hexane was 
used in the sample preparations steps instead of hep-
tane and benzene, as it is a relatively less toxic extrac-
tion solvent. Furthermore, use of hexane resulted in a 
higher recovery of  >90  % as compared to the published 
lower recoveries (around 83 %) for heptane and benzene 
[16–20].
In short the developed and validated GCMS method 
for diclofenac satisfy all the criteria for US-FDA’s “Guid-
ance for Industry Bioanalytical Method Validation:” [34] 
The method is very reliable and robust for quantitative 
determination of diclofenac in human plasma.
Assay application
The pharmacokinetic study was conducted and applied 
to 30 volunteers who had been given an oral dosage of 
100  mg of diclofenac sodium (Rhumalgan XL 100  mg 
modified-release capsules). The amount of diclofenac 
was determined between 0 and 12  h in human plasma. 
The mean plasma concentration–time curve is shown in 
Fig. 5.
Diclofenac sodium is rapidly absorbed from the gut 
and undergoes first-pass metabolism [17, 36]. Rhumalgan 
XL 100™ capsules give the peak plasma concentrations 
(Cmax) at approximately 2.1  h (Tmax), where Tmax is the 
maximum time at which Cmax was observed after admin-
istration. The total drug exposure, which is the area 
under the curve (AUC) over time was calculated from the 
concentration time data.
According to FDA guidelines, for generic drugs 
studies, the area under the curve (AUC) was calcu-
lated by the Linear Trapezoidal method, by applying, 
non-compartmental data analysis using the PK Solver 2.0 
software (as an Excel add-on).
Here AUC0–∞ is the extrapolated value of the AUC 
curve to infinite time and AUC0–12 is the AUC time-
concentration curve to the last measurable concen-
tration at the 12  h time-point. The mean values of 
pharmacokinetic parameters estimated are shown in 
Table 3 [1–5]. Based on our new GCMS method, drug 
quality parameters like bioavailability and bioequiva-
lence could be estimated accurately based on phar-
macokinetic measures such as AUC and Cmax that are 
reflective of systemic exposure. In humans, the pharma-
cokinetics of diclofenac retention and absorption show 
that it has high inter- and intra-subject variability [3, 
5–7, 9–16]. In light of these previously reported inter- 
and intra- variability, our method (although assayed 
on a relatively small sample of 30 subjects) seems to be 
especially valuable as it showed very small variability 
and high reproducibility.
A possible reason for this reduction in inter- and intra-
individual variability as compared to other methods may 
be the use of new extraction solvents such as hexane 
along with phosphoric acid, acetone and sodium bicarbo-
nate for increased deproteination and PFPA as a robust 
and efficient derivatising agent.
The newly developed and validated method could have 
far reaching impact in pharmacokinetic and bioequiva-
lence studies of diclofenac sodium in human patients. 
The proposed method might be applied to other human 
and animal matrices in future studies for accurate quanti-
tation of diclofenac. This new method will also be instru-
mental in any future drug studies to show bioequivalence 
between generic and innovator drug products.
Conclusions
The developed and validated method for the determi-
nation of diclofenac in human plasma is rapid, sen-
sitive, specific, reproducible and robust, and offers 
Fig. 5 Plasma concentration–time profiles of Diclofenac following a 
single oral dose of 100 mg of modified release capsules (Rhumalgan 
XL). The error bars represent the standard error of mean
Table 3 Pharmacokinetic parameters, where  AUC shows 
area under curve and Cmax shows the peak plasma concen-
tration of  the drug after  administration, Tmax shows time 
to reach Cmax
SD standard deviation
Parameter Mean ± SD Confidence level (95 %)
Cmax (ng/mL) 625 ± 8.4 13.4
Tmax (h) 2.0 ± 0.45 0.72
AUC 0–12 (ng/mL h) 3243 ± 9.8 15.6
AUC 0–∞ (ng/mL h) 3331 ± 8.3 13.1
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better sensitivity than previous methods. It utilizes hex-
ane which is a relatively less toxic extraction solvent as 
compared to heptane and benzene, while phosphoric 
acid, acetone and sodium bicarbonate were used for 
increased deproteination. Due to the very small vari-
ability and high reproducibility this method has been 
proved to be suitable for use in pharmacokinetic studies 
of diclofenac in human plasma, which demonstrates the 
possible adequacy of this assay for clinical studies.
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